Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat + Pembrolizumab in Advanced Solid Tumors
NCT03590054Phase 1Completed
- Sponsor
- Rahul Aggarwal
- Start
- Aug 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abexinostat in urothelial carcinoma (UC), melanoma, non-small cell lung cancer (NSCLC) and 9 more (3 arms), sponsored by Rahul Aggarwal. Primary endpoints: Maximally Tolerated Dose up to 21 days and Objective Response Rate up to 2 years. Started Aug 2018; status: completed.
02
Drugs
abexinostat
03
Conditions
urothelial carcinoma (UC)melanomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT03590054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590054.